Refine by
Bladder Cancer Articles & Analysis
33 news found
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in ...
While DNA is largely identical in all cells, RNA fluctuates considerably both in presence and relative concentrations. The variation reflects the underlying cause of a cell’s character and thus RNA analysis gives a more accurate view of the state cells are in compared to DNA analysis. Gene expression levels are important to analyse, and quantitative RNA sequencing is the most informative ...
Also, the early detection of cancer is often limited by high false-positives and/or poor sensitivity to early-stage cancer. ...
Treos maintains full ownership of PolyPEPI1018. About Colorectal Cancer Colorectal cancer (CRC) is the third most common cancer and cause of death in the United States and the third leading cause of cancer-related deaths worldwide. ...
In this moderated poster presentation, the frequency of fibroblast growth factor receptor (FGFR) alterations in high-risk non-muscle invasive bladder cancer (HR-NMIBC) and the association with bacillus Calmette-Guérin (BCG) outcome will be discussed. The GARNER Study is the largest HR-NMIBC real-world patient cohort ever assembled with both clinical and ...
MTAP deletion is one of the most common gene deletions seen in cancers including lung, bladder, and pancreatic cancer, and is associated with poor prognosis. MAT2A is defined as a synthetic lethality target in MTAP-deleted cancers and plays an essential role in producing S-adenosylmethionine (SAM), a molecule involved in cell ...
The Promaxo MRI enabled platform aims for more accurate prostate cancer detection with fewer side effects.” “On positive momentum, we are pleased to add and welcome Arizona Urology to our growing network of physician practices, as our technology enables safe and effective point of care diagnostic biopsies and treatment of cancers, overcoming known ...
In partnering with Promaxo, we are bringing minimally invasive, office based MRI to Beverly Hills, California, with a clinical focus on MR guided biopsies and treatments such as high intensity focused ultrasound (HIFU) of the prostate cancer.” “We continue to build upon our growing network of physician practices and are pleased to collaborate with Beverly Hills ...
The meeting includes state-of-the-art translational topics on prostate, kidney, and bladder cancer, as well as strategies in urologic oncology will be discussed. ...
At first follow-up ureteroscopy, four patients had a complete response, four patients had a partial response, one of whom (with a history of low-grade bladder cancer) also had a bladder tumor. Four of the seven patients who have had more than one surveillance ureteroscopy had an initial complete response. ...
As a result of this encouraging data, we are excited to leverage the Mayo Clinic’s clinical expertise to more deeply study PolyPEPI1018’s potential to address the variability of patients’ responses to cancer immunotherapies.” OBERTO 201 is a single arm, open-label, investigator-initiated Phase 1b trial evaluating 15 patients with metastatic colorectal ...
(Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced the initiation of its Phase 3 ENVISION study of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). ...
Depending on its effectiveness in NSCLC, VTP-600 could be evaluated in other types of cancer in the future, including breast, bowel, bladder and melanoma. ...
(Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare conferences in January: 40th Annual J.P. ...
“Our technology enables safe and effective point of care diagnostic biopsies and treatment of cancers, overcoming limitations of traditional MRIs, and paving way for our $3 billion addressable market for in-office prostate procedures. ...
(Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that the first patient has received their first dose in its home instillation study of UGN-102 in patients with low-grade, intermediate-risk non-muscle invasive bladder cancer ...
Initially, urologists at Northern Health will use Cxbladder Monitor to help manage patients undergoing surveillance following treatment of their bladder cancer. Cxbladder Monitor will be used to identify those patients who can safely forego or defer a flexible cystoscopy at their next scheduled hospital visit. Once implemented, the service will be extended to use ...
NEW YORK, Sept. 20, 2021 /PRNewswire/ -- Data presented from a cross-validation study at the American Urological Association's (AUA) 2021 Annual Meeting confirms that the miR Sentinel® Prostate Cancer Test can detect and risk-classify prostate cancer at the molecular level with predictive accuracy of over 90%, based on a single urine sample. This validation study follows and confirms the ...
NEW YORK and SAN JUAN, Puerto Rico, Sept. 1, 2021 /PRNewswire/ -- miR Scientific, LLC, a healthcare company focused on transforming global cancer management, the Governor of Puerto Rico, Pedro Pierluisi, and the Puerto Rico Health Insurance Administration ("ASES") join forces today to officially make September 1 "Prostate Cancer Prevention Day". This urgent awareness team effort occurs while the ...
Department of Defense Congressionally Directed Medical Research Program. About Colorectal Cancer Colorectal cancer (CRC) is the third most common cancer and cause of death in the United States and the third leading cause of cancer-related deaths worldwide. ...